ciprofloxacin/celecoxib (CogniC) / NeuroSense Therap - LARVOL DELTA

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update (PRNewswire) - "Currently, NeuroSense is preparing a Phase 2 double-blind proof-of-concept clinical study in AD. Regulatory submissions and site readiness have been ongoing during Q3 2023 and the first patient enrolled is expected in December 2023."

Enrollment status • New P2 trial • Alzheimer's Disease • CNS Disorders

NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results (PRNewswire) - "NeuroSense Therapeutics Ltd...today announced it has terminated its previously established 'at-the-market' ('ATM') equity offering program. The termination will take effect at the close of business on October 4th, 2023, following the 3-day termination process of the ATM offering. 'Having completed enrollment in our Phase 2b ALS trial in the second quarter, we continue to dose and monitor patients for the 6-month double blind portion of the study. We also expect to enroll our first patient in our new Phase 2 Alzheimer's disease study in the coming weeks. With clarity on our R&D and operating expenses, we are confident that our Company is fully funded into the second quarter of 2024,' stated NeuroSense Founder and CEO, Alon Ben-Noon. 'With our extensive use of biomarkers in the Phase 2b study, we are optimistic about PrimeC's mechanism of action and its corresponding clinical results anticipated in Q4 2023.'"

Enrollment closed • Financing • New P2 trial • P2b data • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders

NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer’s Biomarker Study (PRNewswire) - “NeuroSense Therapeutics Ltd…announced results from a biomarker study conducted to evaluate the potential of CogniC…Preliminary results revealed high levels of TDP-43 in people who suffer from AD, when compared to the healthy control group. These findings provide additional support for TDP-43 pathology as an integral part of AD, reinforcing the growing body of evidence in AD research regarding the role of TDP-43 in neurodegenerative pathologies. TDP-43 has been found in up to 57% of AD cases and aggregates of TDP-43 have been shown to be cytotoxic both in vitro and in vivo…‘we are now preparing to carry out a clinical proof-of-concept study in conjunction with a leading AD clinic. The study is expected to commence in 2023…’"

Biomarker • Clinical data • New trial • Alzheimer's Disease • CNS Disorders